Navigation Links
Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA(TM) in the U.S.
Date:8/26/2009
CHADDS FORD, Pa., Aug. 26 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.
FORTESTA, a patented 2 percent testosterone transdermal gel for testosterone replacement therapy in male hypogonadism, utilizes a metered dose delivery system designed to permit accurate dose adjustment to individual patient requirements. This product is in registration in the U.S., where the Food and Drug Administration (FDA) is currently reviewing ProStrakan's New Drug Application submission.
Under the terms of the agreement, Endo Pharmaceuticals has agreed to make an upfront payment to ProStrakan of $10 million, with the potential for up to $40 million more in milestone payments by the end of 2010 for regulatory approval and the achievement of certain commercial milestones. Endo Pharmaceuticals has also agreed to pay ProStrakan an additional $160 million upon the achievement of certain sales targets. ProStrakan will exclusively supply FORTESTA to Endo Pharmaceuticals in the U.S. for an undisclosed supply price.
"We are committed to advancing men's health with effective new medicines. Being in a position to potentially offer this treatment, alongside our new long-acting injectable testosterone product, will help fill an important gap in testosterone replacement," said David Holveck, president and chief executive officer of Endo Pharmaceuticals. "This treatment option is synergistic with our recent therapeutic expansion and strengthens our portfolio in urology and endocrinology."
About FORTESTA
FORTESTA (branded variously as Tostran, Tostrex
'/>"/>
| SOURCE Endo Pharmaceuticals Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. Endo Pharmaceuticals Announces Cash Tender Offer for Any and All Outstanding Ledgemont PhaRMA(SM) Secured 16% Notes
2. Robin Leedy & Associates Wins Social Media Program For Union Springs Pharmaceuticals
3. Adamas Pharmaceuticals Expands Management Team; Names Michael D. Coffee and Amy K. Patick to Executive Positions
4. Raptor Pharmaceuticals Raises $5 Million
5. Cumberland Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 27, 2009
6. The Rossbacher Law Firm, Hagens Berman Sobol Shapiro LLP, Wilentz Goldman & Spitzer, P.A., Reed Smith LLP and Thompson Hine LLP, Announce the Proposed Settlement of a Class Action Lawsuit Concerning Estratest and Solvay Pharmaceuticals, Inc.
7. NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting
8. Warner Chilcott Acquires P&Gs Global Pharmaceuticals Business
9. Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN)
10. Sound Pharmaceuticals Receives an Office of Naval Research Award for Its Hearing Loss Research and Development
11. Adamas Pharmaceuticals Raises $40 Million in Series D Financing
Post Your Comments:
(Date:6/19/2013)... 19, 2013 The Journal of Parasitology ... today’s computer software, it creates questions of ethics. For ... As an already published case shows, scientific publications need ... The Journal of Parasitology features a ... a 2004 article published in the Journal of the ...
(Date:6/19/2013)... HOUSTON - In a major international study led by ... Center, the targeted therapy ibrutinib continues to show remarkable ... cell lymphoma (MCL). , The most recent interim findings ... in the New England Journal of Medicine . ... the 54th American Society of Hematology Annual Meeting and ...
(Date:6/19/2013)... published in the June 19 online edition of the ... researchers from the University of California, San Diego School ... take place when cardiac regeneration occurs in zebrafish after ... various cell lines in the heart are more plastic, ... previously thought. , More importantly, the research reveals a ...
(Date:6/19/2013)... understanding of the genetic process that can lead to ... lesions for some women, and also raises a warning ... cases suggesting they could actually trigger the cancer ... a clearer picture of the chromosomal and genetic changes ... to chronic infection and, in less than 1 percent ...
(Date:6/19/2013)... University of Iowa study reveals significant disparities between ... completing substance abuse treatment programs. Moreover, these disparities ... "Our findings suggest that for most states there,s ... of psychiatry and biostatistics. "There are strong racial ... to complete substance abuse treatment programs successfully, and ...
Breaking Medicine News(10 mins):Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:Genetics of cervical cancer raise concern about antiviral therapy in some cases 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3[0] Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines[0] Ibrutinib continues strong showing against mantle cell lymphoma[0] Fate of the heart: Researchers track cellular events leading to cardiac regeneration[0] Genetics of cervical cancer raise concern about antiviral therapy in some cases[0] States vary widely on success rates for minorities in drug treatment programs
... out-of-pocket health care costs, CAMP HILL, Pa., Sept. ... to help consumers compare health plan options and,choose one ... is available,to consumers on Highmark member Web sites. ... said Kim,Bellard, Vice President of eMarketing and Customer Relationship ...
... President, SEIU-UHW and SEIU California State ... ... My name is Sal Rosselli,and I,m the President of SEIU United ... workers in healthcare, the,public sector, property services, and other industries throughout ...
... choices , MONDAY, Sept. 10 (HealthDay News) -- U.S. and ... a comprehensive recommendation on how much of what types of ... diets. , Both the American Dietetic Association and the Dietitians ... that 20 percent to 30 percent of energy needs should ...
... -- In lifesaving procedures to open blocked heart arteries ... use of the more expensive drug, abciximab, justified over ... Mayo Clinic study to be published in the current ... and now available as an e-publication, offers clinicians the ...
... Hundreds of Institutional Investors to Attend Conference, ... Board: SKVI / Website: http://www.skinvisible.com ), the ... topically,applied dermatology products, today announced that Mr. Terry ... annual Merriman Curhan Ford & Co.,Investor Summit on ...
... Through November 2007 -, GLENDALE, Calif., ... for applications for the 2008-2009 PowerBar Team ... athletes, coaches,nutritionists, trainers and health and fitness ... invited to visit, http://www.powerbar.com/teamelite/application to submit ...
Cached Medicine News:Health News:Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers 2Health News:SEIU Endorses AB 8, 'An Opportunity to Make History' 2Health News:Experts Sort Out Good Fats From Bad 2Health News:Skinvisible to Present at Merriman Curhan Ford & Co.'s Investor Summit 2007 2Health News:PowerBar Issues Open Call for 2008-2009 PowerBar Team Elite(TM) Athlete Sponsorship Program 2Highmark Blue Shield Introduces New Health Plan Comparison Tool for ConsumersSEIU Endorses AB 8, 'An Opportunity to Make History'Experts Sort Out Good Fats From Bad2 drugs equally effective for heart patients undergoing angioplasty, Mayo study findsSkinvisible to Present at Merriman Curhan Ford & Co.'s Investor Summit 2007PowerBar Issues Open Call for 2008-2009 PowerBar Team Elite(TM) Athlete Sponsorship Program
(Date:6/19/2013)... CHICAGO , June 19, 2013 Dr. ... been named one of four recipients of the 2013 ... achievement in applied medical informatics. "On ... for his recognition in leadership, innovation and continuous efforts ... Paul M. Black , President and Chief Executive Officer ...
(Date:6/19/2013)... June 19, 2013 ... market research report is available in ... Licensing, Investments and M&A Deals and ... http://www.reportlinker.com/p0925641/Partnerships-Licensing-Investments-and-MA-Deals-and-Trends-for-May-2013-in-Pharmaceuticals.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Investment_Banking ... Deals and Trends for May 2013 ...
(Date:6/19/2013)... The Physician-Patient Alliance for Health & Safety recently released three ... urgently address this issue has been emphasized by The ... device alarm safety in hospitals." According to The Joint Commission ... there were 98 alarm related events reported, of which: ... resulted in permanent loss of function (13%) , 5 ...
Breaking Medicine Technology:Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 2Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 3Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 4Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 5Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 2Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 3Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 4Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 5Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 6Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 7Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 8Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 9Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 10Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 11Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 12Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 13Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3[0] Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award[0] Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals[0] Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals
... , MALVERN, Pa. and FRAZER, Pa., Nov. ... and Cephalon, Inc. (Nasdaq: CEPH ) today announced results ... a treatment for pediatric eosinophilic esophagitis (EoE). The study ... changes in esophageal eosinophil levels and clinical symptoms. Analyses ...
... , IRVINE, Calif., Nov. 23 ... infection prevention solution provider, announced today the acquisition ... Europe, a privately held developer of innovative disinfection ... of the acquisition were not disclosed. , ...
Cached Medicine Technology:Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 2Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 3Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 4Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 5ASP Announces Acquisition of Gloster Europe to Help Reduce Infections in Healthcare Facilities 2Nitinol Tipless Stone Basket...
1.5 Fr Nitinol Tipless Stone Basket...
Rapid latex agglutination test for presumptive identification of E. coli serogroup O157:H7 isolates. Colorimetric with red O157 latex and blue H7 latex....
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
Medicine Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |